Cover Image
市場調查報告書

勃奇氏淋巴瘤:開發中產品分析

Burkitt Lymphoma - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 213068
出版日期 內容資訊 英文 124 Pages
訂單完成後即時交付
價格
Back to Top
勃奇氏淋巴瘤:開發中產品分析 Burkitt Lymphoma - Pipeline Review, H2 2016
出版日期: 2016年11月09日 內容資訊: 英文 124 Pages
簡介

所謂勃奇氏淋巴瘤是指發生於被稱作B細胞的免疫細胞之非何杰金氏淋巴瘤癌症。症狀有發熱和盜汗、淋巴結腫脹、體重減少等,是男性及HIV/AIDS等免疫系統不全患者常見的疾病。治療法有化療及放射線療法等。

本報告涵括全球勃奇氏淋巴瘤治療藥的開發平台,提供您目前開發平台狀況和最新趨勢,藥物簡介,主要企業及他們開發中的產品評估等資訊,為您概述為以下內容。

簡介

  • 調查範圍

勃奇氏淋巴瘤概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

勃奇氏淋巴瘤:企業開發中的治療藥

勃奇氏淋巴瘤:大學/機關研究中的治療藥

勃奇氏淋巴瘤:開發中產品概況

  • 臨床階段的產品
  • 初期階段的產品

勃奇氏淋巴瘤:企業開發中的產品

勃奇氏淋巴瘤:大學/機關研究中的產品

勃奇氏淋巴瘤的治療藥的開發企業

  • AbbVie Inc.
  • Arvinas, Inc.
  • AstraZeneca Plc
  • Bluebird bio, Inc.
  • Constellation Pharmaceuticals, Inc.
  • Immunomedics, Inc.
  • Karyopharm Therapeutics, Inc.
  • Millennium Pharmaceuticals, Inc.
  • Seattle Genetics, Inc.
  • 武田藥品工業
  • Theravectys SA

勃奇氏淋巴瘤:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

勃奇氏淋巴瘤:最近的開發平台趨勢

勃奇氏淋巴瘤:暫停中的計劃

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8631IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Burkitt Lymphoma - Pipeline Review, H2 2016, provides an overview of the Burkitt Lymphoma (Oncology) pipeline landscape.

Burkitt lymphoma is a form of non-Hodgkin's lymphoma in which cancer starts in immune cells called B-cells. Symptoms include fever, night sweats, swollen lymph nodes and weight loss. The disease is more common in males and people with compromised immune systems, such as those with HIV/AIDS. Treatment includes chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Burkitt Lymphoma - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Burkitt Lymphoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Burkitt Lymphoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Burkitt Lymphoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 1, 3 and 13 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 2 molecules, respectively.Burkitt Lymphoma.

Burkitt Lymphoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Burkitt Lymphoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Burkitt Lymphoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Burkitt Lymphoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Burkitt Lymphoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Burkitt Lymphoma (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Burkitt Lymphoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Burkitt Lymphoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Burkitt Lymphoma Overview
  • Therapeutics Development
    • Pipeline Products for Burkitt Lymphoma - Overview
    • Pipeline Products for Burkitt Lymphoma - Comparative Analysis
  • Burkitt Lymphoma - Therapeutics under Development by Companies
  • Burkitt Lymphoma - Therapeutics under Investigation by Universities/Institutes
  • Burkitt Lymphoma - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Burkitt Lymphoma - Products under Development by Companies
  • Burkitt Lymphoma - Products under Investigation by Universities/Institutes
  • Burkitt Lymphoma - Companies Involved in Therapeutics Development
    • AbbVie Inc
    • Arvinas, Inc.
    • bluebird bio, Inc.
    • Boehringer Ingelheim GmbH
    • Constellation Pharmaceuticals, Inc.
    • Immunomedics, Inc.
    • Karyopharm Therapeutics, Inc.
    • Millennium Pharmaceuticals Inc
    • Patrys Limited
    • Seattle Genetics, Inc.
    • Takeda Pharmaceutical Company Limited
    • Theravectys SA
  • Burkitt Lymphoma - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • 19-3s - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • 20-3s - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • alisertib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ARV-825 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • bb-2121 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy to Target CD19 for ALL - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy to Target CD30 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • denintuzumab mafodotin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • E1-3s - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Epstein-Barr virus vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ibrutinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ixazomib citrate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody Conjugate to Target CD20 for Leukemia and Burkitt Lymphoma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PATLM-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • selinexor - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SH-7129 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SH-7133 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SH-7139 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit BET for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • volasertib trihydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Burkitt Lymphoma - Dormant Projects
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Burkitt Lymphoma, H2 2016
  • Number of Products under Development for Burkitt Lymphoma - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Burkitt Lymphoma - Pipeline by AbbVie Inc, H2 2016
  • Burkitt Lymphoma - Pipeline by Arvinas, Inc., H2 2016
  • Burkitt Lymphoma - Pipeline by bluebird bio, Inc., H2 2016
  • Burkitt Lymphoma - Pipeline by Boehringer Ingelheim GmbH, H2 2016
  • Burkitt Lymphoma - Pipeline by Constellation Pharmaceuticals, Inc., H2 2016
  • Burkitt Lymphoma - Pipeline by Immunomedics, Inc., H2 2016
  • Burkitt Lymphoma - Pipeline by Karyopharm Therapeutics, Inc., H2 2016
  • Burkitt Lymphoma - Pipeline by Millennium Pharmaceuticals Inc, H2 2016
  • Burkitt Lymphoma - Pipeline by Patrys Limited, H2 2016
  • Burkitt Lymphoma - Pipeline by Seattle Genetics, Inc., H2 2016
  • Burkitt Lymphoma - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
  • Burkitt Lymphoma - Pipeline by Theravectys SA, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Burkitt Lymphoma - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Burkitt Lymphoma, H2 2016
  • Number of Products under Development for Burkitt Lymphoma - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top